Comments for BioSante Pharma (NASDAQ:BPAX): LibiGel Provides Big Upside Potential at http://www.biomedreports.com , comment 1 to 1 out of 1 comments http://www.biomedreports.com Wed, 08 Feb 2012 17:59:42 +0100 FeedCreator 1.7.3 http://www.biomedreports.com/2009093011364/biosante-pharma-nasdaqbpax-libigel-provides-big-upside-potential.html#comment-951 I am a private investor and compliment you on your coverage of BPAX. I know BioSante very well and Antares (AIS, even better; from whom BPAX has licensed both Elestrin and Libi-Gel. Any responsible recommendation of BioSante should offer for consider AIS as an investment opportunity. I believe AIS has much of the upside potential of Elestrin and Libi-Gel without any of the accompanying risk - and AIS is a much more diversified company with extremely attractive upside potential. Should you wish to hear more of my thoughts on AIS - please advise and I will e-mail my research. Thank you - Bob Taplinger - BOB TAPLINGER Wed, 30 Sep 2009 03:42:07 +0100